Aquestive Therapeutics Inc is a biopharmaceutical company that has established itself as a major player in the US and international markets. With a mission to tackle unmet medical needs, Aquestive has focused on identifying, developing, and commercializing a range of products designed to treat a diverse range of conditions. Its flagship products include Sympazan, Suboxone, Zuplenz, and Azstarys. Sympazan is an oral soluble film formulation of clobazam, geared towards treating lennox-gastaut syndrome. Suboxone is a sublingual film formulation of buprenorphine and naloxone, designed to alleviate opioid dependence. Zuplenz is an oral soluble film formulation of ondansetron, aimed at treating nausea and vomiting associated with chemotherapy and post-operative recovery. And Azstarys is a once-daily product designed to treat attention deficit hyperactivity disorder. The company's proprietary product candidates also comprise of Libervant and Exservan. Libervant is a buccal soluble film formulation of diazepam for the treatment of seizures, while Exservan is an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Aquestive's proprietary pipeline of complex molecule products includes AQST-108, and AQST-109. AQST-108 is a sublingual film formulation delivering systematic epinephrine for the treatment of conditions other than anaphylaxis, while AQST-109 is an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. The company is also developing KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics Inc was incorporated in 2004 and is headquartered in Warren, New Jersey.
Aquestive Therapeutics's ticker is AQST
The company's shares trade on the NASDAQ stock exchange
They are based in Warren, New Jersey
There are 51-200 employees working at Aquestive Therapeutics
It is aquestive.com
Aquestive Therapeutics is in the Healthcare sector